AX-2026-041233
L-Glutathione (reduced) · 200 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2602-U1840
- Report ID
- AX-2026-041233
- Compound
- L-Glutathione (reduced)
- Compound class
- Short bioregulator peptides
- Supplier
- WWB — Wuhan Wansheng Biotechnology Co., Ltd.
- Batch / lot
- WWB-2602-U1840
- Declared label claim
- 200mg
- Laboratory
- Janoshik Analytical
- Assay date
- 17 Mar 2026
- Submitted
- 10 Apr 2026
- Quarter
- 2026-Q1
- Submitter
- el.mwangi
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.48 | % area | ≥ 98.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.52 | % area | ≤ 1.5 | PASS |
| Largest single impurity | RP-HPLC — glutathione disulfide (GSSG, +305 Da) | 0.36 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 307.0838 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 307.0849 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +3.6 | ppm | ± 20 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 90.29 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.82 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 233.05 | mg | 200 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 209.326 | mg | 200 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 104.7 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 9.29 | % | ≤ 12.0 | PASS |
| Counter-ion | no ionisable counter-ion expected | N/A | — | not applicable | NOT TESTED |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.42 | % | — | NOT TESTED |
| Endotoxin | kinetic chromogenic LAL | 0.25 | EU/mg | ≤ 5.0 | PASS |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White cake, partial shrinkage from vial wall | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 7.16 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 4.33 | min | 4.28 ± 0.20 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.03 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 50,058 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs S-sulfonate adduct (+80 Da) | 1.76 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | L-Glutathione (reduced) — main peak | 4.33 | 4,835,036 | 99.48 | — |
| 2 | glutathione disulfide (GSSG, +305 Da) | 4.85 | 17,497 | 0.36 | +304.984 |
| 3 | S-sulfonate adduct (+80 Da) | 4.19 | 4,374 | 0.09 | +79.957 |
| 4 | γ-Glu-Cys (−57 Da) | 4.15 | 2,430 | 0.05 | -57.021 |
| 5 | cysteinyl-glycine (−129 Da) | 4.09 | 972 | 0.02 | -129.043 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 307.0838 Da, computed from C10H17N3O6S. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 1+ | 308.0911 | 308.0922 | 0.0011 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 9.29 |
| Counter-ion | none expected | 0.00 |
| Residual solvent + inorganic residue | estimated | 0.42 |
| Total peptide content | by difference | 90.29 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.66 | 99.48 | divergence +0.18 pp vs batch median |
| Total impurities (% area) | 0.34 | 0.52 | |
| Largest single impurity (% area) | 0.13 | 0.36 | |
| Water (%) | not stated | 9.29 | |
| Counter-ion (%) | 8.4 | N/A | |
| Peptide content (%w/w) | 87.5 | 90.29 | |
| Endotoxin (EU/mg) | not stated | 0.25 | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (2–8 °C, 15 d) → laboratory (courier, ambient, 12 d) → assay.
- Assay date
- 17 Mar 2026
- Submitted to the index
- 10 Apr 2026
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- METHOD LIMITED
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot WWB-2602-U1840 n=5
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041229 | WWB-2602-U1840 | Medutest | 2026-Q1 | 99.89 | 9.32 | 99.8 | Buyer-sourced | 0 | PASS |
| AX-2026-041230 | WWB-2602-U1840 | PeptideMeter | 2026-Q1 | 99.09 | 9.22 | 94.2 | Laboratory-retained | 0 | PASS |
| AX-2026-041231 | WWB-2602-U1840 | PeptideMeter | 2026-Q1 | 99.85 | 9.56 | 103.4 | Buyer-sourced | 0 | PASS |
| AX-2026-041232 | WWB-2602-U1840 | Medutest | 2026-Q1 | 99.36 | 9.11 | 94.9 | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043429 | WXT | WXT-2605-B3833 | Nordanalyt | 2026-Q3 | 98.48 | 6.58 | 96.9 | Supplier-supplied | 1 | FAIL |
| AX-2026-043424 | WXT | WXT-2605-B3833 | PeptideMeter | 2026-Q3 | 98.37 | 6.86 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043166 | GL Biochem | GLBI-2606-S7352 | Janoshik | 2026-Q3 | 99.01 | 8.84 | 105.4 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-043423 | WXT | WXT-2605-B3833 | Janoshik | 2026-Q3 | 97.86 | 6.66 | 93.4 | Buyer-sourced | 0 | FAIL |
| AX-2026-043426 | WXT | WXT-2605-B3833 | Kestrel | 2026-Q3 | 98.83 | 6.32 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043425 | WXT | WXT-2605-B3833 | Janoshik | 2026-Q3 | 98.77 | 6.35 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043431 | WXT | WXT-2605-B3833 | Nordanalyt | 2026-Q3 | 97.94 | 6.18 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043427 | WXT | WXT-2605-B3833 | Medutest | 2026-Q3 | 97.67 | 6.08 | — | Buyer-sourced | 1 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041275 | Liraglutide | WWB-2607-X2189 | Nordanalyt | 2026-Q3 | 99.33 | 4.39 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041334 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.93 | 4.62 | 99.9 | Buyer-sourced | 0 | PASS |
| AX-2026-041337 | Semaglutide | WWB-2606-N3192 | Nordanalyt | 2026-Q3 | 99.52 | 3.92 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041335 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 99.15 | 4.27 | 98.9 | Buyer-sourced | 0 | PASS |
| AX-2026-041271 | Liraglutide | WWB-2607-X2189 | Medutest | 2026-Q3 | 99.52 | 4.57 | 97.4 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041328 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.99 | 4.47 | 106.1 | Buyer-sourced | 0 | PASS |
| AX-2026-041333 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 99.18 | 4.51 | 90.4 | Laboratory-retained | 0 | PASS |
| AX-2026-041273 | Liraglutide | WWB-2607-X2189 | Janoshik | 2026-Q3 | 99.31 | 5.52 | 104.8 | Buyer-sourced | 1 | MARGINAL |